Sabin Research & Development News: Sabin's Ebola Sudan Vaccine in Uganda

Published on December 12, 2022

The Sabin Vaccine Institute is happy to announce it is the first organization to provide the World Health Organization (WHO) a vaccine to fight the Ebola Sudan outbreak in Uganda. The outbreak, now abating, began in September and has killed at least 55 people to date. Sabin’s Ebola Sudan vaccine is a single-dose and has been found to be safe and produce fast and reliable immunity based on data from Phase 1 clinical trials and non-human primate studies. Over 1,000 doses of Sabin’s vaccine are now in Uganda, with 8,500 more to be made available to the WHO throughout January, and approximately 25,000 further doses expected to be supplied early next year. 
Read more about this development here: https://www.sabin.org/resources/sabin-vaccine-institute-delivers-ebola-sudan-vaccine-to-fight-outbreak-in-uganda/ 

Other news

Cervical Cancer Elimination Day of Action 2022

November 18, 2022
The 17th of November 2022 marked two years since the world came together for a global day of action toward eliminating cervical cancer. In 2020, the World Health Organization (WHO) launched the Global Strategy to Accelerate the Elimination of Cervical Cancer by 2030. A major pillar of this plan is preventing cervical cancer through HPV vaccination, with the goal of 90% vaccination of all girls by

VARN 2023 Call for Abstracts

December 15, 2022
The second annual Vaccination Acceptance Research Network conference, VARN2023, will be held from June 13-15, 2023, in Bangkok, Thailand, hosted jointly with UNICEF. Sabin and UNICEF invite the submission of both research-based and measurable, practice-based abstracts depicting either completed work or ongoing projects to be completed by June 2023. Applications accepted in both English and French.